Ovarian Cancer News & Features
The discovery of three genetic variants associated with mucinous ovarian carcinomas (MOCs) offers the first evidence of genetic susceptibility in this type of ovarian cancer.
Researchers have identified a molecule that may play a central role in chemotherapy resistance in patients with the most common ovarian cancer.
Women with advanced ovarian cancer have fewer side effects and tend to have a better quality of life if given chemotherapy before surgery.
A new screening method utilizing protein analysis can detect ovarian cancer in twice as many women as conventional strategies, according to the latest trial results.
miR-506 may play a role in chemotherapy resistance in patients with ovarian cancer.
Ovarian Cancer Clinical Trials
- Growing up with cancer: Understanding the challenges to adolescents and young adults (AYAs) coping with cancer
- Navigators have a key role in using genetics and genomics for cancer risk identification
- Younger, unrelated donors with high T cell counts make better matches for patients undergoing stem cell transplant
- Distinct triple-positive subtypes identified in breast cancer
- Managing oral oncology/hematology treatments in your practice
- Survivorship care plans: The shift back to primary care
- Scientists identify key to preventing metastatic breast cancer
- Cancer and intimate partner violence: Could you tell if one of your patients is a victim?
- Composing a CoC-compliant community health needs assessment (CHNA)
- Cancer Clusters (Fact Sheet)
- Comorbid conditions associated with worse lung cancer survival
- Benefits found for screening colonoscopies of higher quality
- High-grade cervical lesions declining in young women
- Early relapse of follicular lymphoma may increase risk of death
- Study identifies perception gap in incidence, impact of CINV/RINV
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|